Aphios Corporation Announces Launch of SuperCool Gingerol for Calming Stomachs and Healthy Digestion
November 17, 2004
Woburn, MA — November 17, 2004 — Aphios Corporation today announced the launch of its SuperCool™ Gingerol dietary supplement product for calming stomachs and healthy digestion.

SuperCool™ Gingerol is an advanced formulation of an enhanced gingerols and shogaols fraction of Ginger or Zingiber, the dried rhizome of Zingiber officinale Roscoe (Family Zingiberaceae) known commercially as Jamaica ginger, African ginger and China ginger. Aphios' SuperCool™ Gingerol product is standardized against gingerols and shogaols. Ginger has become widely accepted as a treatment for nausea. Ginger is listed on the FDA's GRAS (generally regarded as safe) list as a food.

SuperCool™ Gingerol's sister product Zindol™ is currently in a multi-center Phase II/III, dose-finding, placebo-controlled clinical trial for nausea in cancer patients undergoing chemotherapy. Nausea and emesis (an act or instance of vomiting) are not diseases but symptoms associated with several conditions including flatulence, motion sickness, surgery, and pregnancy. Trevor Castor, CEO, Aphios states, "There is still a great deal of room for improvement in the control of nausea and emesis. A desirable attribute in any substitute or additional antiemetic medication would be the absence of clinically significant adverse effects."

Environmental friendly and nontoxic SuperFluids™ carbon dioxide technologies (US Patents) were used to discover and are being used to manufacture the active ingredients of SuperCool™ Gingerol. The product is formulated and encapsulated by Pfizer, Inc. in accordance with cGMP (current Good Manufacturing Practices) of the United States Food and Drug Administration (FDA).

SuperCool™ Gingerol has not been evaluated by the FDA and is not intended to diagnose, treat, cure or prevent disease. As with any dietary supplement, consumers should consult their physician before taking this product. Research leading to the development of SuperCool™ Gingerol was funded, in part, by the National Cancer Institute (NCI), National Institutes of Health (NIH).

Aphios Corporation is developing enabling SuperFluids™ technology platforms for improving the discovery, manufacturing, pathogenic safety and delivery of therapeutic drugs and utilizing these platforms to develop enhanced therapeutics for health maintenance and the treatment of human diseases with a focus on infectious diseases, oncology and quality-of-life medicines.

For more information on SuperCool™ Gingerol, please visit www.supercoolhealth.com.